EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY-NC 4.0

Efficacy and safety of 2–4 mg brexpiprazole in the management of schizophrenia: A systematic review and meta‐analysis

Sher Bano, Aashan Ahmad, Abdul Haseeb Mohammed, Ismailova Rushana Nurbekovna, Saja Saad, Noor Fatima, Muhammad Bilal Akbar, Zainab Salahuddin, Sadikun Nabi, Mohammad Mustafa Ababneh, Laiba Ajmal, Sidra Hariss und 3 weitere

Psychiatry and Clinical Neurosciences Reports · 2026-06 · 5 (2)

DOI: 10.1002/pcn5.70332 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Psychiatry and Clinical Neurosciences Reports, online erschienen am 12.04.2026. Verfasst von Sher Bano und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Psychology Shifa Tameer-e-Millat University Islamabad Pakistan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Brexpiprazole 2–4 mg daily is a novel dopamine D2 partial agonist approved for schizophrenia and improves effectiveness and tolerance by balancing D2, 5‐HT1A, and 5‐HT2A effects. This review assesses current evidence on its efficacy and safety within this dose range. PubMed, ScienceDirect, and The Cochrane Library were searched for trials published between 2011 and 2025 using specific keywords. Eligibility criteria included schizophrenia patients diagnosed using DSM‐IV, DSM‐IV‐TR, DSM‐5, or ICD‐10, with intervention being 2–4 mg of brexpiprazole. Positive and Negative Syndrome Scale (PANSS) score and Clinical Global Impression ‐ Severity scale (CGI‐S) were the primary efficacy endpoints, and treatment‐related adverse events were used to assess efficacy. Subgroup analysis was planned between the two dosage groups. The quality of randomized controlled trials (RCTs) was evaluated using the ROB2 tool, and the protocol registration was completed in PROSPERO. Among 464 retrieved articles, five trials with 2182 participants were found to be eligible. Brexpiprazole significantly improved total PANSS scores (mean difference [MD] −5.76; 95% confidence interval [CI] −7.69 to −3.83; p < 0.00001), positive subscale scores, negative subscale scores, and CGI‐S scores (MD −1.35; 95% CI −1.87 to −0.84; p < 0.00001). The treatment‐emergent adverse events were similar to placebo, and the risk of discontinuation was less with brexpiprazole (risk ratio 0.58; 95% CI 0.430.77; p = 0.0002). The most usual extrapyramidal symptom was akathisia. Brexpiprazole 2–4 mg showed significant improvements in PANSS and CGI‐S scores, with a lower risk of treatment discontinuation. These findings support its efficacy and tolerability in managing schizophrenia.

Schlagwörter

Stichwörter der Autor:innen

CGI‐SPANSSbrexpiprazolerandomized controlled trialsschizophrenia

Autor:innen und Institutionen

  • Department of Clinical Psychology Shifa Tameer-e-Millat University Islamabad Pakistan.
  • Department of Neurology Pakistan Institute of Medical Sciences Islamabad Pakistan.
  • Department of Fundamental Medical Sciences Kimyo International University in Tashkent (KIUT) Tashkent Uzbekistan.
  • Department of Medicine Kimyo International University in Tashkent (KIUT) Tashkent Uzbekistan.
  • Department of Internal Medicine Jordan University Hospital Amman Jordan.
  • Department of Biology Academy of Health and Medicine, Somerset County Vocational and Technical High School Hillsborough New Jersey USA.

ORCID-Profile: Raouf Khan

Zitieren

APA

Bano, S., Ahmad, A., Mohammed, A. H., Nurbekovna, I. R., Saad, S., Fatima, N., Akbar, M. B., Salahuddin, Z., Nabi, S., Ababneh, M. M., Ajmal, L., Hariss, S., Manaf, H., Saleh, F., & Khan, R. (2026). Efficacy and safety of 2–4 mg brexpiprazole in the management of schizophrenia: A systematic review and meta‐analysis. Psychiatry and Clinical Neurosciences Reports, 5(2). https://doi.org/10.1002/pcn5.70332

Vancouver

Bano S, Ahmad A, Mohammed AH, Nurbekovna IR, Saad S, Fatima N, et al. Efficacy and safety of 2–4 mg brexpiprazole in the management of schizophrenia: A systematic review and meta‐analysis. Psychiatry and Clinical Neurosciences Reports. 2026;5(2). doi:10.1002/pcn5.70332

BibTeX
@article{Bano2026,
  author = {Bano, Sher and Ahmad, Aashan and Mohammed, Abdul Haseeb and Nurbekovna, Ismailova Rushana and Saad, Saja and Fatima, Noor and Akbar, Muhammad Bilal and Salahuddin, Zainab and Nabi, Sadikun and Ababneh, Mohammad Mustafa and Ajmal, Laiba and Hariss, Sidra and Manaf, Hiba and Saleh, Farah and Khan, Raouf},
  title = {Efficacy and safety of 2–4 mg brexpiprazole in the management of schizophrenia: A systematic review and meta‐analysis},
  journal = {Psychiatry and Clinical Neurosciences Reports},
  year = {2026},
  volume = {5},
  number = {2},
  doi = {10.1002/pcn5.70332}
}
Kostenlos starten →